MedAlliance Archives - Medical Design Sourcing

Cordis acquires drug-eluting balloon maker MedAlliance for up to $1.135B

MedAlliance announced today that Cordis acquired it for a total consideration that could reach up to $1.135 billion.

The companies initially announced the planned deal in October of last year.

Cordis, which develops interventional cardiovascular and endovascular technologies, made a $35 million investment last year. Its upfront closing payment totals $200 million, with achievement milestones reaching up to $125 million. With up to $775 million available in commercial milestones through 2029, the total consideration comes to $1.135 billion.

MedAlliance develops the Selution SLR sustained sirolimus drug-eluting balloon program. The company said its product family complements Cordis’ existing product portfolio along with its sales, marketing and distribution expertise.

Selution SLR provides a controlled sustained drug release, similar to a drug-eluting stent. It features unique micro-reservoirs made of biodegradable polymer intermixed with siro…

MedAlliance picks up FDA IDE nod for drug-eluting balloon

MedAlliance announced today that its novel sirolimus-eluting balloon received conditional FDA investigational device exemption (IDE).

Geneva, Switzerland-based MedAlliance can now initiate its pivotal clinical trial for the treatment of coronary de novo lesions.

Get the full story at our sister site, Drug Delivery Business News.

MedAlliance picks up FDA IDE nod for drug-eluting balloon

MedAlliance announced today that its novel sirolimus-eluting balloon received conditional FDA investigational device exemption (IDE).

Geneva, Switzerland-based MedAlliance can now initiate its pivotal clinical trial for the treatment of coronary de novo lesions.

Get the full story at our sister site, Drug Delivery Business News.

The top 10 cardiac device stories of 2022

[Image from Pixabay]From pulsed-field ablation to non-invasive monitoring, this was an exciting year for cardiac device tech.

Here are the top 10 cardiac device stories from MassDevice and its sister sites:

10. Medtronic to pay Acutus $17M following EU MDR submission of left-heart access portfolio

Earlier this year, Acutus agreed to sell its left-heart access portfolio to Medtronic for $50 million.

9. Abbott confirms first implants of its dual-chamber leadless pacemaker system

The company designed its i2i technology to provide beat-by-beat communication between two leadless pacemakers, with one positioned on the right ventricle and the other in the right atrium.

8. Boston Scientific completes $1.75B Baylis Medical acquisition

The deal expanded Boston Scientific’s electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross transseptal platforms. It also gained a family of guidewires, sheaths an…

Cordis to acquire MedAlliance for initial $235M

Cordis this week announced it will acquire MedAlliance for a total consideration of over $1 billion.

Through the deal, Cordis will pay an initial investment of $35 million and an upfront closing payment of $200 million. In addition, it will pay regulatory achievement milestones of up to $125 million. Plus, commercial milestone payments could reach up to $775 million through 2029.

The total value of the deal could reach over $1.135 billion.

Cordis, which develops and manufactures interventional cardiovascular and end-vascular technology, will acquire MedAlliance’s coronary and peripheral artery treatment devices. MedAlliance tech includes its sustained sirolimus drug-eluting balloon Selution SLR.

“We are very fortunate to find a partner like Cordis, with its strong history of innovation. The company that introduced sirolimus drug-eluting stents (DES) in 1999 will be introducing the Selution SLR sustained limus release sirolimus drug-elu…

MedAlliance enrolls first patient in study of drug-eluting balloon for treating erectile dysfunction

MedAlliance announced today that it enrolled the first patient in a trial for its drug-eluting ballon in treating erectile dysfunction.

Geneva, Switzerland-based MedAlliance said an 82-year-old Taiwanese man enrolled in the initial trial. It will evaluate the Selution SLR sirolimus-eluting balloon for the treatment of erectile dysfunction (ED).

Get the full story at our sister site, Drug Delivery Business News.

First patient enrolled in MedAlliance’s drug-eluting balloon trial

MedAlliance announced today that the first patient was enrolled in a trial of its Selution SLR sirolimus-eluting balloon.

Last month, the company received FDA investigational device exemption (IDE) for the Selution SLR drug-eluting balloon, which it designed to provide a controlled sustained drug release, similar to a drug-eluting stent. The FDA IDE BTK (below-the-knee) Selution4BTK clinical trial comes on the heels of that IDE. Selution SLR was granted FDA breakthrough device designation in 2019.

Get the full story at our sister site, Drug Delivery Business News.

FDA grants IDE for MedAlliance’s sirolimus-eluting balloon

MedAlliance announced today that it received FDA investigational device exemption (IDE) for its Selution SLR drug-eluting balloon.

Geneva, Switzerland-based MedAlliance designed its Selution SLR (sustained limus release) novel sirolimus-eluting balloon to provide a controlled sustained drug release, similar to a drug-eluting stent.

Get the full story at our sister site, Drug Delivery Business News.

MedAlliance touts 18-month data for treating lesions with sirolimus-eluting balloon

MedAlliance today touted late-breaking clinical trial data demonstrating positive outcomes with its Selution SLR drug-eluting balloon.

The company presented 18-month results from its Prestige below-the-knee (BTK) study evaluating the safety and performance of Selution SLR in treating long tibial occlusive lesions (TASC C & D) in patients with critical limb ischemia (CLI) at VIVA21.

Get the full story at our sister site, Drug Delivery Business News.

MedAlliance completes trial enrollment for sirolimus-eluting balloon for treating PAD

MedAlliance announced today that it completed patient enrollment for a trial of its Selution SLR sirolimus drug-eluting balloon.

Geneva, Switzerland-based MedAlliance, along with Japanese partner MDK Medical, completed the enrollment following the acceptance of a Clinical Trial Notification (CTN) by the Pharmaceutical Products and Medical Devices Agency (PMDA) of Japan in June 2020.

Get the full story at our sister site, Drug Delivery Business News.

MedAlliance enrolls first patient in drug-eluting balloon trial for erectile dysfunction

MedAlliance announced today that it enrolled the first patient in an erectile dysfunction (ED) feasibility study with its drug-eluting balloon (DEB).

Nyon, Switzerland-based MedAlliance’s first patient was enrolled in the trial at the University of Rome Tor Vergata, Italy, under the direction of principal investigator Giuseppe Sangiorgi, a professor of cardiovascular interventional pathology.

Get the full story at our sister site, Drug Delivery Business News.

MedAlliance closes enrollment for sirolimus-coated balloon trial

MedAlliance announced today that it closed patient enrollment for its clinical trial of the Selution SLR 018 BLF drug-eluting balloon.

Nyon, Switzerland-based MedAlliance designed its Selution SLR 018 BLF for the treatment of patients with disease below the knee. The company touts Selution SLR as the first device of its kind to receive an “innovative device designation” from the FDA.

Get the full story at our sister site, Drug Delivery Business News.